Lexicon Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapies to treat various diseases, including rare genetic disorders and chronic conditions
Through its cutting-edge research and development initiatives, Lexicon aims to leverage its proprietary drug discovery platform to identify and advance new treatment options that can significantly improve patient outcomes. The company is committed to making a positive impact on healthcare by addressing unmet medical needs through its portfolio of potential therapeutic candidates.
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies— Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ) —each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025.
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December.
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
San Diego, CA -- (SBWIRE) -- 05/09/2022 -- Certain directors of Lexicon Pharmaceuticals, Inc are under investigation over potential breaches of fiduciary duties.
